Advanced search×

ADAM-17: a target to increase chemotherapeutic efficacy in colorectal cancer?

Adam M AM Lee and Robert B RB Diasio

Clin Cancer Res 16(13):3319-21 (2010) PMID 20570925

Chemotherapy-induced activation of ADAM-17 results in increased growth factor shedding and activation of growth factor receptor-mediated pro-survival response. Enhanced ADAM-17 activity and HER ligand shedding results in resistance to chemotherapy in CRC. Therapies that decrease ADAM-17 activity in conjunction with current treatments may enhance response rates in advanced CRC patients.

DOI: 10.1158/1078-0432.CCR-10-1059
Version: za2963e q8za1 q8zbe q8zc6 q8zdb q8zed q8zf1 q8zgd

Similar articles you may find interesting…

  1. AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development.
    Samir N SN Khleif, James H JH Doroshow, ...

    Clin Cancer Res 16(13):3299-318 (2010) PMID 20501613

    Recent discoveries in cancer biology have greatly increased our understanding of cancer at the molecular and cellular level, but translating this knowledge into safe and effective therapies for cancer patients has proved to be challenging. There is a growing imperative to modernize t...
  2. Alignment-free sequence comparison (II): theoretical power of comparison statistics.
    Lin Wan, Gesine Reinert, ... Michael S Waterman

    J Comput Biol 17(11):1467-90 (2010) PMID 20973742

    We study the power of the statistic D(2), which counts the number of matching k-tuples between two sequences, as well as [Formula: see text], which uses centralized counts, and [Formula: see text], which is a self-standardized version, both from a theoretical viewpoint and numerically, providing an...
    View PDF